Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel

Peer Review reports

Original Submission
21 Nov 2010	Submitted	Original manuscript
2 Dec 2010	Author responded	Author comments - Eva Johanna Kantelhardt
Resubmission - Version 2
2 Dec 2010	Submitted	Manuscript version 2
13 Dec 2010	Author responded	Author comments - Eva Johanna Kantelhardt
Resubmission - Version 3
13 Dec 2010	Submitted	Manuscript version 3
15 Feb 2011	Reviewed	Reviewer Report - Michael Dixon
1 Mar 2011	Author responded	Author comments - Eva Johanna Kantelhardt
Resubmission - Version 4
1 Mar 2011	Submitted	Manuscript version 4
11 Mar 2011	Author responded	Author comments - Eva Johanna Kantelhardt
Resubmission - Version 5
11 Mar 2011	Submitted	Manuscript version 5
19 Mar 2011	Author responded	Author comments - Eva Johanna Kantelhardt
Resubmission - Version 6
19 Mar 2011	Submitted	Manuscript version 6
Publishing
16 Apr 2011	Editorially accepted
16 Apr 2011	Article published	10.1186/1471-2407-11-140

Back to article page